On March 2, 2018, manufacturers Biogen and AbbVie announced that they were withdrawing Zinbryta (Daclizumab) from the market worldwide. The drug is no longer available.
For more details about this treatment, visit:
Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA (daclizumab) for Relapsing Multiple Sclerosis - Biogen
We never share your personal information with anyone.Continue with Facebook Sign up with your email